PANACEABIO388.00

Panacea Biotec Limited

· Pharma & Health
₹ CrorePeersSAIPARENTHIKALINDOCODCALWINDLASHESTERBIOSOLARASYNCOMFMcap ₹2,378 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation36.734.833.1
+ Finance Costs3.63.96.1
+ Interest Income-8.4-7.7-4.2
+ Dividend Income-0.00.00.0
+ Fair Value (Gains) / Losses-3.40.00.0
+ Unrealised FX (Gain) / Loss0.10.85.3
+ Other Non-cash Items-38.0-1.3-1.3
Changes in Working Capital
+ Inventories24.2-35.720.9
+ Trade Receivables — Current3.0-15.81.3
+ Other Financial Assets — Current-4.3-62.110.4
+ Other Financial Assets — Non-current-0.6-1.01.4
+ Other Current Assets-5.0-15.632.9
+ Other Non-current Assets-17.628.7-34.0
+ Trade Payables — Current-17.674.3-42.4
+ Other Financial Liabilities — Current-3.1-7.9-4.4
+ Other Financial Liabilities — Non-current0.40.00.0
+ Other Current Liabilities40.7-6.531.5
+ Other Non-current Liabilities-10.325.0-10.1
+ Provisions — Current-0.90.63.1
+ Provisions — Non-current1.37.53.3
Cash from Operating Activities
Profit Before Tax (per I/S)1.5-8.0-7.4-10.4
+ Total Adjustments (incl. Working Capital)0.921.853.0
Cash from Operations (pre-tax)2.413.945.6
+ Other Inflows / (Outflows) — Operating0.0-40.3-22.5
+ Income Taxes Paid2.51.06.5
Cash from Operating Activities-0.1-27.416.7
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)77.750.354.1
+ Disp of Fixed Assets6.70.00.0
+ Disp of Investment Property0.00.60.0
+ Dividends Received — Investing0.00.00.0
+ Interest Received — Investing8.47.74.2
+ Other Inflows / (Outflows) — Investing72.9107.09.4
Cash from Investing Activities10.265.0-40.5
Cash from Financing Activities
+ Proceeds from Borrowings0.00.03.4
+ Repayment of Borrowings0.20.00.0
+ Interest Paid2.62.74.4
Cash from Financing Activities-2.8-2.7-1.1
Net Changes in Cash (pre-FX)7.335.0-24.9
+ Effect of FX Rate Changes on Cash0.00.00.0
Net Changes in Cash7.335.0-24.8
Closing Cash47.2
Reference Items
EBITDA-20.1-25.9-4.72.2
EBITDA Margin %-3.59-4.63-0.730.33
Free Cash Flow (CFO − Capex)-77.8-77.7-37.4-37.4
Free Cash Flow to Equity-79.1-40.4
Free Cash Flow per Basic Share-12.69-12.67-6.10-6.10
Cash Flow to Net Income0.073.14-2.33
Cash Paid for Taxes2.51.06.5
Cash Paid for Interest2.62.74.4
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.